Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Receivables: 2024-2025

Historic Receivables for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to $16.7 million.

  • Day One Biopharmaceuticals' Receivables rose 92.03% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.3 million, marking a year-over-year change of. This contributed to the annual value of $13.9 million for FY2024, which is N/A change from last year.
  • Day One Biopharmaceuticals' Receivables amounted to $16.7 million in Q3 2025, which was down 15.11% from $19.7 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Receivables peaked at $19.7 million during Q2 2025, and registered a low of $8.7 million during Q3 2024.
  • In the last 2 years, Day One Biopharmaceuticals' Receivables had a median value of $15.3 million in 2024 and averaged $14.4 million.
  • Data for Day One Biopharmaceuticals' Receivables shows a peak YoY soared of 115.29% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Day One Biopharmaceuticals' Receivables stood at $13.9 million in 2024, then spiked by 92.03% to $16.7 million in 2025.
  • Its last three reported values are $16.7 million in Q3 2025, $19.7 million for Q2 2025, and $18.1 million during Q1 2025.